816 related articles for article (PubMed ID: 27273296)
1. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
[TBL] [Abstract][Full Text] [Related]
2. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.
Obici L; Kuks JB; Buades J; Adams D; Suhr OB; Coelho T; Kyriakides T;
Curr Opin Neurol; 2016 Feb; 29 Suppl 1(Suppl 1):S27-35. PubMed ID: 26734953
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation.
Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y
J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715
[TBL] [Abstract][Full Text] [Related]
7. [Transthyretin familial amyloid polyneuropathy].
Kopishinskaya SV
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):82-89. PubMed ID: 30499502
[TBL] [Abstract][Full Text] [Related]
8. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
[TBL] [Abstract][Full Text] [Related]
9. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L
J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427
[TBL] [Abstract][Full Text] [Related]
10. Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy.
Leibou L; Frand J; Sadeh M; Lossos A; Kremer E; Livneh A; Yarnitsky D; Herman O; Dabby R
Isr Med Assoc J; 2012 Nov; 14(11):662-5. PubMed ID: 23240369
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
12. A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
Jimenez-Zepeda VH; Bahlis NJ; Gilbertson J; Rendell N; Porcari R; Lachmann HJ; Gillmore JD; Hawkins PN; Rowczenio DM
Amyloid; 2015 Mar; 22(1):26-30. PubMed ID: 25430583
[TBL] [Abstract][Full Text] [Related]
13. [Presentations of transthyretin associated familial amyloid polyneuropathy in Argentina].
Chaves M; Bettini M; Marciano S; Sáez S; Cristiano E; Rugiero M
Medicina (B Aires); 2016; 76(2):105-8. PubMed ID: 27135849
[TBL] [Abstract][Full Text] [Related]
14. Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.
Martens B; De Pauw M; De Bleecker JL
Acta Neurol Belg; 2018 Jun; 118(2):179-185. PubMed ID: 29524093
[TBL] [Abstract][Full Text] [Related]
15. [Familial amyloid polyneuropathy].
Yamashita T; Ando Y; Uchino M
Brain Nerve; 2011 Jun; 63(6):583-95. PubMed ID: 21613661
[TBL] [Abstract][Full Text] [Related]
16. Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
Adams D; Beaudonnet G; Adam C; Lacroix C; Théaudin M; Cauquil C; Labeyrie C
Rev Neurol (Paris); 2016 Oct; 172(10):645-652. PubMed ID: 27663057
[TBL] [Abstract][Full Text] [Related]
17. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy.
Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y
J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783
[TBL] [Abstract][Full Text] [Related]
18. Familial amyloidotic polyneuropathy and transthyretin.
Nagasaka T
Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
[TBL] [Abstract][Full Text] [Related]
19. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
Li H; Zhang Y; Cao L; Xiong R; Zhang B; Wu L; Zhao Z; Chen SD
Drug Des Devel Ther; 2014; 8():2121-8. PubMed ID: 25382970
[TBL] [Abstract][Full Text] [Related]
20. Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan.
Miyake Z; Nakamagoe K; Ezawa N; Yoshinaga T; Hashimoto R; Sato T; Sekijima Y; Tamaoka A
Intern Med; 2019 Mar; 58(5):713-718. PubMed ID: 30333406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
